MedTrace Logo

Advair Pediatric Once-Daily

NCT00920959 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 908

Last updated 2016-09-15

No results posted yet for this study

Summary

To demonstrate if once-daily dosing of ADVAIR 100/50 once-daily has superior efficacy and comparable safety compared with FP 100mcg once-daily in pediatric subjects 4 to 11 years of age with asthma.

Conditions

Interventions

DRUG

FP 100mcg

Once-daily dosing

DRUG

FSC 100/50mcg

Once-daily dosing

DRUG

Placebo

Once-daily dosing

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2004-01-31
Completion
2004-01-31

Countries

  • United States
  • Argentina
  • Chile
  • Peru
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00920959 on ClinicalTrials.gov